SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

AstraZeneca Pharma India informs about appointment of senior management personnel

25 Feb 2025 Evaluate

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, AstraZeneca Pharma India has informed that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company have approved the appointment of Harish Dash as Senior Director, Commercial IT & Digital, with effect from March 3, 2025. In this regard, it has enclosed the details as required under the SEBI Circular SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023, attached as Annexure – A.

The above information is a part of company’s filings submitted to BSE.


Astrazeneca Pharma I Share Price

8472.00 17.60 (0.21%)
22-Apr-2026 11:03 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1657.10
Dr. Reddys Lab 1218.45
Cipla 1230.25
Zydus Lifesciences 931.10
Lupin 2312.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×